Tim Smith

In this interview segment on his AAAAI presentation, Dellon described some of the study’s limitations and more about the condition of eosinophilic esophagitis.

In an interview regarding his AAAAI poster session, Dellon described a sub-analysis of new phase 3 trial data on dupilumab for eosinophilic esophagitis patients.

In his HCPLive interview at the 2023 AAAAI conference, Gallo elaborated on his team’s research into the skin microbiome’s connection to atopic dermatitis and future research.

In phase 3 data presented at the AAAAI conference, an investigational intranasal epinephrine spray was found to have higher and more sustained pharmacokinetics than the standard reference product.

In an interview with HCPLive, Gallo described his AAAAI presentation on the function of the skin microbiome, as well as the microbiome’s connection to atopic dermatitis.

New data from the 2023 AAAAI conference showed that the mice with atopic dermatitis used in the study had different responses to ILC2 activity depending on their age.

In another segment of his interview at the 2023 AAAAI conference, Shamji spoke about comparisons between subcutaneous and sublingual immunotherapies.

In an interview at the 2023 AAAAI conference, Shamji spoke about the key points made in his presentation titled ‘Biomarkers for the Response to Allergen Immunotherapy.’

In an interview segment with Kirby, she described her views on the need for future research into povorcitinib for hidradenitis suppurativa patients, as well as her outlook on treatment.

In the interview, Kirby discussed recent trial data on povorcitinib indicating significant decreases in total abscess and inflammatory nodule count for hidradenitis suppurativa patients.

Chovatiya discussed his Winter Clinical Miami presentation, common concerns over black box warnings for JAK inhibitors, and unmet needs of alopecia areata patients.

In his latest HCPLive interview, regarding a presentation at Winter Clinical Miami, Chovatiya spoke about recent JAK inhibitor developments, alopecia areata, baricitinib, and more.

In her latest HCPLive interview, Ablon discusses her Winter Clinical Miami dermatology conference presentation ‘Evaluating the Aesthetic Patient’ and its biggest takeaways.

In another segment of her interview with HCPLive, Graber explored some of the latest treatment developments for acne and rosacea covered in her 2023 Winter Clinical Miami presentation.

In an HCPLive interview on her Winter Clinical Miami presentation, Graber describes several new developments in the dermatology space regarding acne and rosacea treatments.

In another segment of his interview, Mark Lebwohl, MD, discussed the various ways to address different psoriasis patients depending on their backgrounds with obesity, cancer, and psoriatic arthritis.

In his recent interview, Mark Lebwohl, MD, spoke about his Winter Clinical Miami presentation titled ‘Psoriasis: Which Drug for Which Patient?’ and some of its highlights.

In an interview with Maria Teresa García-Romero, MD, MPH, a discussion was held regarding the need for a morphea severity tool for pediatric patients.

New research into global trends in atopic dermatitis over 3 decades assessed regional and income differences in adolescent eczema patients.

Mental health outcomes for those with hidradenitis suppurativa who have had a previous surgery were explored in recent research.

Recent findings found that an association existed between late-in-life depression and air pollution over time for the older US population.

In another interview segment, Karan Lal, DO, MS, spoke on the side effects of JAK inhibitors and on the FDA approval of abrocitinib for younger atopic dermatitis patients.

During his latest HCPLive interview, Karan Lal, DO, describes some of the major takeaways from his presentations at the South Beach Symposium, including information on atopic dermatitis.

New research explored associations between lesions resulting from Degos and diffuse cutaneous systemic sclerosis.

An interview segment with Alexa Kimball, MD, MPH, in which she describes further updates on 52 week trial data in the SUNRISE and SUNSHINE trials for HS.

A recent interview with Alexa Kimball, MD, MPH, regarding recent data from the SUNRISE and SUNSHINE studies on secukinumab for HS patients.

In recent phase 2 trial data, a monoclonal antibody called vixarelimab showed strong results for prurigo nodularis treatment.

Research was conducted into the development of a tool for assessing morphea disease severity in pediatric patients.

New research into patient-focused deprescribing strategies for those dealing with the effects of polypharmacy in hospital and post-acute care facilities.

New research was conducted regarding air pollution and other elements affecting asthma cases in urbanized settings.